Table 2.
Cancer | Mutation Rates | |||
---|---|---|---|---|
KRAS | KRAS Exon 2 Mutations Rate | KRAS Exon 3 Mutations Rate | KRAS Exon 4 Rate Considering the Total of KRAS Mutations | |
NSCLC | 25–30% | 34% | 1.89% | 0.24% |
Lung AC | 30–35% | 27% | 7% | <1% |
SCC | 3–4% | 7% | <3% | <0.5% |
AC: AdenoCarcinoma; NSCLC: Non-Small Cell Lung Cancer; SCC: Squamous-Cell Carcinoma (AACR Project GENIE Consortium, 2017 [7]).